热门资讯> 正文

Humacyte因Symvess出售给军事治疗机构而上涨

2025-07-24 02:30

Humacyte (NASDAQ:HUMA) shares jumped on Wednesday following the announcement of the first sale of Symvess, its vascular repair product, to a U.S. Military Treatment Facility.
The sale comes after the U.S. Defense Logistics Agency recently approved the ECAT listing for Symvess.
The shares of the company are up 16%.
ECAT is an internet solution through which commercial catalogs of multiple manufacturers and distributors are available at discounted prices for the U.S. Department of Defense and other federal agencies.

More on Humacyte

Humacyte: Revenue Ramp From Symvess Incoming
Humacyte Paradoxically Scales Back As Symvess Begins Its Long Journey
Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript
Humacyte jumps as DoD issues ECAT listing approval for Symvess
Humacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。